Annals of Hematology

, Volume 90, Issue 3, pp 331–341

Long-term outcomes of HLA-matched sibling compared with mismatched related and unrelated donor hematopoietic stem cell transplantation for chronic phase chronic myelogenous leukemia: a single institution experience in China

  • Qi-fa Liu
  • Xiao-jun Xu
  • Yin-kui Chen
  • Jing Sun
  • Yu Zhang
  • Zhi-ping Fan
  • Dan Xu
  • Qian-li Jiang
  • Yong-qiang Wei
  • Fen Huang
  • Ru Feng
  • Xiao-li Liu
  • Bing Xu
  • Fan-Yi Meng
Original Article

DOI: 10.1007/s00277-010-1081-3

Cite this article as:
Liu, Q., Xu, X., Chen, Y. et al. Ann Hematol (2011) 90: 331. doi:10.1007/s00277-010-1081-3

Abstract

Allogeneic hematopoetic stem cell transplantation (allo-HSCT) remains the only curative therapy for chronic myelogenous leukemia (CML). In this study, the long-term outcomes of HLA-matched sibling donor (MSD) with mismatched related donor (MRD) and unrelated donor (URD) transplantation for CML in the first chronic phase (CML-CP1) using different graft vs. host disease (GVHD) prophylaxis regimens according to donor source and the degree of HLA matching were compared. The data of 91 patients with CML-CP1 were analyzed with respect to GVHD, overall survival (OS), and transplant-related mortality (TRM). The incidence of grade II–IV acute GVHD was 25.5% in the MSD and 40.5% in the MRD/URD group (P = 0.133). The 1-year cumulative incidence of chronic GVHD was not different between the MSD and the MRD/URD groups, while extensive chronic GVHD was different between the two groups (31.9% vs. 10.8%, P = 0.023). The 5-year cumulative relapse rate was not different between the MSD and the MRD/URD groups, while TRM was different between the two groups (6.6% vs. 26.3%, P = 0.010). The 5-year cumulative OS was 90.9%, 71.5%, and 85.4% in the MSD, the MRD/URD, and the HLA allele-matched URD transplantation, respectively (MSD vs. MRD/URD, P = 0.013; MSD vs. HLA allele-matched URD, P = 0.437). In conclusion, survival in HLA allele-matched URD is equivalent to MSD, but in MRD and mismatched URD is inferior to MSD in patients with CML-CP1 undergoing allo-HSCT using different GVHD prophylaxis regimens according to donor source and degree of HLA matching. Patients undergoing MRD/URD transplantation have an equal quality of life as patients undergoing MSD transplantation.

Keywords

Chronic myelogenous leukemia Allogeneic transplantation Donor Graft vs. host disease prophylaxis 

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Qi-fa Liu
    • 1
  • Xiao-jun Xu
    • 1
  • Yin-kui Chen
    • 1
  • Jing Sun
    • 1
  • Yu Zhang
    • 1
  • Zhi-ping Fan
    • 1
  • Dan Xu
    • 1
  • Qian-li Jiang
    • 1
  • Yong-qiang Wei
    • 1
  • Fen Huang
    • 1
  • Ru Feng
    • 1
  • Xiao-li Liu
    • 1
  • Bing Xu
    • 1
  • Fan-Yi Meng
    • 1
  1. 1.Department HematologyNanfang Hospital, Southern Medical UniversityGuangzhouChina

Personalised recommendations